**Aztreonam and ceftazidime: evidence of in vivo cross-allergenicity**

AZTREONAM is a monocyclic β-lactam antibiotic which appears to lack cross-reactivity with other classes of β-lactams. Nevertheless, in vitro studies have shown cross-allergenicity between aztreonam and ceftazidime (1), a third-generation cephalosporin which is the only drug with the same side-chain (Fig. 1). These facts suggest that reactions to aztreonam are caused by its side-chain.

We present a case of sensitization to aztreonam with cross-reactivity to ceftazidime, proved by skin tests and tolerance of other β-lactams. No cases of in vivo cross-allergenicity between aztreonam and ceftazidime have been previously reported.

Our patient was a 57-year-old man who had had a cutaneous reaction to clindamycin 6 years before. He had a personal history of ischemic heart disease and left pneumonectomy because of cryptogenic lung hypoplasia with recurrent respiratory infections, and this was treated with large courses of many antibiotic agents. At the moment, pleural empyema was diagnosed, and the patient was started on amoxicillin/clavulanate (1 g IV) and aztreonam (1 g IV). Two hours after receiving the first dose of both drugs, he developed a widespread pruriginous maculopapular eruption. Amoxicillin/clavulanate was stopped and aztreonam was continued, but the latter was withdrawn 2 days later because of the increase of the skin reaction. Corticosteroids and antihistamines were needed to control the reaction, which had completely disappeared after 8 days.

Specific IgE was determined for penicillin and amoxicillin (Pharmacia® CAP System), and proved to be negative. Skin prick and intradermal tests were performed with penicilloyl polylsine and a minor determinant mixture (Allergopen® Merck), benzylpenicillin (10 000 UI/ml), amoxicillin (20 mg/ml), amoxicillin/clavulanate (20/5 mg/ml), cephadine (20 mg/ml), ceftazidime (20 mg/ml), and aztreonam (2 mg/ml). The results were positive with aztreonam and ceftazidime in intradermal tests, with persistence of the reaction after 24 h. We performed patch tests with amoxicillin, amoxicillin/clavulanate, ceftazidime, and aztreonam, at concentrations of 20% in vaseline, obtaining positive results with ceftazidime and aztreonam. Negative results were obtained in 10 control subjects. We performed challenge tests with amoxicillin, amoxicillin/clavulanate, and
three cephalosporins (cephradine, cefuroxime, and ceftriaxone) at therapeutic doses. These drugs were well tolerated.

From the results, a diagnosis of sensitization to aztreonam was established, and the patient was forbidden to use ceftazidime.

Aztreonam, the main representative of the monocyclic β-lactam antibiotics (monobactams), is known to cause IgE-mediated reactions (urticaria/angioedema, anaphylaxis) (2, 3), even on the first exposure (4). Other adverse reactions are rash, eosinophilia, gastrointestinal disorders, elevation of liver enzymes, and erythema multiforme.

Aztreonam has been found to be well tolerated by subjects allergic to other β-lactam antibiotics (5), and to be only weakly immunogenic (1). A few cases of sensitization to aztreonam and good tolerance of other β-lactam antibiotics (including ceftazidime) have been reported (2, 3). In *in vitro* studies, cross-reactivity between aztreonam and ceftazidime has been described (1), although we have not found previous cases of cross-allergenicity proved by *in vivo* testing (intradermal and patch test) in the scientific literature.

The patient’s tolerance of amoxicillin, cephradine, cefuroxime, and ceftriaxone supports the hypothesis of the side-chain implication.

We recommend that ceftazidime be prohibited in cases of allergic reaction to aztreonam, at least before performing skin tests, because of the evidence of cross-reactivity.

Key words: aztreonam; ceftazidime; cross-reactivity

A. Pérez Pimentel*, M. Gómez Martínez, A. Mínguez Mena, A. Trampal González, S. de Paz Arranz, M. Rodríguez Mosquera

*Servicio de Alergia
Clínica Puerta de Hierro
C/ San Martín de Porres, 4
28035 Madrid
Spain

Accepted for publication 2 December 1997
Copyright © Munksgaard 1998
ALLERGY 1998:53:624–625

REFERENCES

Eczema-like plaques to enoxaparin

RARELY, immunologically mediated hypersensitivity reactions to heparins can occur. We present a patient who developed infiltrated, eczematous plaques at the sites of subcutaneous injections of enoxaparin.

A 50-year-old nonsmoker woman, with no personal or family history of allergy, underwent total vaginal hysterectomy because of uterine prolapse. Some years before, the patient had had two operations, one for kidney stones and the other for venous insufficiency. During admission for hysterectomy, the patient was treated with prophylactic sodium enoxaparin (Clexane 20), once a day, injected subcutaneously in the abdominal wall. Three days after beginning this therapy, the patient complained of itching and tightness at the sites where heparin was injected. Clinical examination revealed four 3–5-cm erythematous and infiltrated plaques (Fig. 1). No systemic reaction was observed. Skin biopsy of one of these lesions showed spongiotic dermatitis. Treatment with topical corticosteroids was established. Recovery was complete in 7 days. One month later, an allergologic study was performed. Patch tests with the standard contact antigen panel of the Spanish Contact Dermatitis Research Group, vehicle and drug series, were positive for nickel sulfate and miconazole. Patch tests using enoxaparin, as is, in the Finn-chamber, and Leukotest showed eczematous changes at 48 and 96 h. Prick and intradermal tests with sodium enoxaparin 5000 and 500 Ul/ml, calcium nadroparin 10 000 and 1000 Ul/ml, and sodium heparin 5000 and 500 Ul/ml were carried out on the volar surface of the forearm. For intradermal tests, 0.02 ml of each substance was injected with 1 ml insulin syringes and 25-gauge needles, giving a bleb approximately 3 mm in diameter. Readings were done at 15 min, and 1, 24, and 72 h in order to rule out immediate or late responses. Immediate (15 min) and 1-h readings were negative for all substances. At 24 h, intradermal tests with sodium enoxaparin 5000 and 500 Ul/ml and calcium nadroparin 10 000 Ul/ml showed positive eryth-
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.